Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Efficacy and Safety Study of Nalbuphine ER Tablets for the Treatment of Refractory Chronic Cough

Next Previous
Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Efficacy and Safety Study of Nalbuphine ER Tablets for the Treatment of Refractory Chronic Cough

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nalbuphine (Primary)
  • Indications Cough
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RIVER
  • Sponsors Trevi Therapeutics

Most Recent Events

  • 30 Apr 2026 According to a Trevi Therapeutics media release, data from this trial are accepted for a poster presentation at the American Thoracic Society (ATS) 2026 International Conference held May 15 - 20, 2026, in Orlando, Florida.
  • 09 Mar 2026 According to a Trevi Therapeutics media release, company announced completion of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). At the meeting, the Company gained overall alignment on the plan for the remaining development program.
  • 13 Nov 2025 According to a Trevi Therapeutics media release, results from this study were presented at both the CHEST 2025 Annual Meeting as well as at the ERS Congress 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top